Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
NRX Pharmaceuticals ( (NRXP) ) has issued an update.
NRx Pharmaceuticals has appointed Michael Abrams as the new Chief Financial Officer, succeeding Richard Narido, who will focus on acquisition opportunities for HOPE Therapeutics. Abrams, an industry veteran with extensive experience in biotechnology and investment banking, aims to help NRx transition from a pre-revenue entity to a profitable biotechnology company. This move marks a significant step in NRx’s strategy to leverage Abrams’ expertise in financial operations and capital raising to strengthen its position in the market.
Learn more about NRXP stock on TipRanks’ Stock Analysis page.
